VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

ALVAC-FL- env/gag
Vaccine Information
  • Vaccine Name: ALVAC-FL- env/gag
  • Target Pathogen: Feline leukemia virus
  • Target Disease: Feline leukemia virus infection
  • Vaccine Ontology ID: VO_0004740
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • env from FeLV-A/Glasgow gene engineering:
    • Type: Recombinant vector construction
    • Description: Two ALVAC (canarypox virus)-based recombinant viruses expressing the feline leukemia virus (FeLV) subgroup A env and gag genes were assessed for their protective efficacy in cats. Both recombinant viruses contained the entire gag gene. ALVAC-FL also expressed the entire envelope glycoprotein, while ALVAC-FL(dl IS) expressed an env-specific gene product deleted of the putative immunosuppressive region (Tartaglia et al., 1993).
    • Detailed Gene Information: Click Here.
  • gag gene engineering:
    • Type: Recombinant protein preparation
    • Description: Two ALVAC (canarypox virus)-based recombinant viruses expressing the feline leukemia virus (FeLV) subgroup A env and gag genes were assessed for their protective efficacy in cats. Both recombinant viruses contained the entire gag gene. ALVAC-FL also expressed the entire envelope glycoprotein, while ALVAC-FL(dl IS) expressed an env-specific gene product deleted of the putative immunosuppressive region (Tartaglia et al., 1993).
    • Detailed Gene Information: Click Here.
  • Vector: ALVAC vaccine vector
  • Preparation: Two ALVAC (canarypox virus)-based recombinant viruses expressing the feline leukemia virus (FeLV) subgroup A env and gag genes (Tartaglia et al., 1993).
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Cat Response

  • Vaccination Protocol: Cats were vaccinated with ALVAC-FL(dI IS) or ALVAC-FL, consisting of two subcutaneous inoculations of 108 PFU at 5 and 2 weeks prior to challenge (Tartaglia et al., 1993).
  • Vaccine Immune Response Type: VO_0003057
  • Challenge Protocol: All cats were challenged by oronasal administration of 2 x 106 FFU of FeLV-A/Glasgow-1 isolate to simulate natural transmission (Tartaglia et al., 1993).
  • Efficacy: Although only 50% of the cats vaccinated with ALVAC-FL(dl IS) were protected against persistent viremia after oronasal exposure to a homologous FeLV isolate, all cats administered ALVAC-FL resisted the challenge exposure. Significantly, protection was afforded in the absence of detectable FeLV-neutralizing antibodies (Tartaglia et al., 1993).
References
Tartaglia et al., 1993: Tartaglia J, Jarrett O, Neil JC, Desmettre P, Paoletti E. Protection of cats against feline leukemia virus by vaccination with a canarypox virus recombinant, ALVAC-FL. Journal of virology. 1993; 67(4); 2370-2375. [PubMed: 8383248].